Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan clinical oncology group study (JCOG9205)

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 54-59

  Ohtsu, Atsushi ^a,b   Shimada, Yasuhiro ^a   Shirao, Kuniaki ^a   Boku, Narikazu ^a   Hyodo, Ichinosuke ^a   Saito, Hiroshi ^a   Yamamichi, Noboru ^a   Miyata, Yoshinori ^a   Ikeda, Nobumasa ^a   Yamamoto, Seiichiro ^a   Fukuda, Haruhiko ^a   Yoshida, Shigeaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; FLUOROURACIL; MITOMYCIN; TEGAFUR; URACIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MALE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 18744373000     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.130     Document Type: Article

References (23)

1. Health and Welfare Statistics Association: The movement of population. J Health Welfare Stat 46 (Suppl):41-72, 1999.
2. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
3. Glimelius B, Hotfmann K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190, 1994.
4. Pyrhonen S, Kuitumen T, Nyandoto P, et al: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995.
5. Kurihara M, Izumi T, Yoshida S, et al: A cooperative randomized study on tegafur plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 82:613-620, 1991.
6. Koizumi W, Kurihara M, Sasai T, et al: A phase II study of combination therapy with 5-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72:658-662, 1993.
7. Shimada Y, Yoshida S, Ohtsu A, et al: A phase II study of EAP (etoposide, adriamycin and cisplatin) in the patients with advanced gastric cancer: Multi-institutional study. J Jpn Soc Cancer Ther 26:280, 1991 (abstract 227).
8. Ohtsu A, Shimada Y, Yoshida S, et al: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A:2091-2093, 1994.
9. Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541-548, 1992.
10. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 253:2061-2067, 1985.
11. Japanese Research Society for Gastric Cancer: Japanese classification of gastric carcinoma. (English edition). Nishi M, Omori Y, and Miwa Y (eds). Part IV. Response assessment of chemotherapy for gastric carcinoma. Kanehara Syuppan, Tokyo, 1995, pp 89-100.
12. Tobinai K, Kohno A, Shimada Y, et al: Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23:250-257, 1993.
13. O'Connell MJ: Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: An old lesson revisited. J Clin Oncol 10:515- 516, 1992.
14. Kim NK, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818, 1993.
15. Cullinan SA, Moertel CG, Wieand HS, et al: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 12:412-416, 1994.
16. Wils JA, Klein HO, Wagener JT, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Group. J Clin Oncol 9:827-831, 1991.
17. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Group. J Clin Oncol 18:2648-2657, 2000.
18. Webb A, Cunningham D, Scarffe H, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261- 267, 1997.
19. Ajani JA: Standard chemotherapy for gastric carcinoma: Is it a myth? J Clin Oncol 18:4001-4003, 2000.
20. Shirao K, Shimada Y, Kondoh H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997.
21. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323, 1999.
22. Sakata Y, Ohtsu A, Horikoshi N, et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720, 1998.
23. Koizumi W, Kurihara M, Nakano S, et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197, 2000.